title: Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) for hepatocellular carcinoma (HCC).
  
  
  METHODS
  The study population was comprised of 164 patients who were treated by TACE alone. Of these patients, 76 underwent TACE using a suspension of DDPH in lipiodol (LPD) (DDPH group), and the remaining 88 underwent TACE with an emulsion of doxorubicin (ADM) with LPD (ADM group). We compared the DDPH group with the ADM group in terms of the objective early response rate, progression free survival (PFS) and overall survival (OS).
  
  
  RESULTS
  The objective early response rate in the DDPH group was significantly higher than that in the ADM group (54% vs 24%, P < 0.001). The PFS rate in the DDPH group was also significantly higher than that in the ADM group (P < 0.001). Moreover, the OS in the DDPH group was significantly longer than that in the ADM group (P = 0.002). Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group, the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia. No other serious complications were observed in either group.
  
  
  CONCLUSIONS
  We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Uchimaru 19-1, Morioka, Iwate 020-8505, Japan. kaz-k@yc4.so-net.ne.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kasai
authors.forename: Akira
authors.initials: A
authors.lastname: Ushio
authors.forename: Kei
authors.initials: K
authors.lastname: Sawara
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Yukiho
authors.initials: Y
authors.lastname: Kasai
authors.forename: Kanta
authors.initials: K
authors.lastname: Oikawa
authors.forename: Hidekatsu
authors.initials: H
authors.lastname: Kuroda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takikawa
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011208:Powders; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D004304:Dosage Forms; D011208:Powders; D002945:Cisplatin